Original Contribution | Published:

Esophageal

Effect of Esomeprazole on Nighttime Heartburn and Sleep Quality in Patients with GERD: A Randomized, Placebo-Controlled Trial

The American Journal of Gastroenterology volume 100, pages 19141922 (2005) | Download Citation

Subjects

Abstract

OBJECTIVES:

Sleep disturbances are common in patients with gastroesophageal reflux disease (GERD). This study examined the effects of esomeprazole on nighttime heartburn, GERD-related sleep disturbances, sleep quality, work productivity, and regular activities.

METHODS:

This multicenter, randomized, double-blind, placebo-controlled trial included adults with GERD-associated sleep disturbances and moderate-to-severe nighttime heartburn (recorded by patient diary during screening). Patients received oral esomeprazole 40 mg (n = 220) or 20 mg (n = 226) or placebo (n = 229) once daily for 4 wk. The primary outcome was relief of nighttime heartburn. Secondary outcomes included resolution of sleep disturbances, sleep quality measured by the Pittsburgh Sleep Quality Index (PSQI) questionnaire, and work productivity measured by the Work Productivity and Activity Impairment Questionnaire.

RESULTS:

Nighttime heartburn was relieved in 53.1% (111/209), 50.5% (111/220), and 12.7% (28/221) of patients who received esomeprazole 40 mg, esomeprazole 20 mg, and placebo, respectively. Differences (95% CI) versus placebo were 40.5% (32.4%, 48.5%) and 37.8% (29.9%, 45.7%) and were highly significant (p < 0.0001). GERD-related sleep disturbances resolved in significantly more (p < 0.0001) patients who received esomeprazole 40 (73.7%) or 20 mg (73.2%) than in those who received placebo (41.2%). Both esomeprazole groups had greater PSQI global score changes from baseline (p < 0.0001 vs placebo) and more (p < 0.0001 vs placebo) work hours saved per week per patient compared with baseline (esomeprazole 40 mg, 11.6 h; esomeprazole 20 mg, 12.3 h; placebo, 6.2 h).

CONCLUSIONS:

Esomeprazole reduced nighttime heartburn and GERD-related sleep disturbances and improved sleep quality and work productivity.

Access optionsAccess options

Rent or Buy article

Get time limited or full article access on ReadCube.

from $8.99

All prices are NET prices.

References

  1. 1.

    . Typical and atypical presentations of gastroesophageal reflux disease. The role of esophageal testing in diagnosis and management. Gastroenterol Clin North Am 1996;25: 75–102.

  2. 2.

    . Epidemiology and natural history of gastro-oesophageal reflux disease. Digestion 1992;51(Suppl):24–29.

  3. 3.

    , , , et al. Sleep dysfunction in patients with gastro-oesophageal reflux disease: Prevalence and response to GERD therapy, a pilot study. Aliment Pharmacol Ther 2004;20: 969–974.

  4. 4.

    , , , et al. Sleep and nocturnal acid reflux in normal subjects and patients with reflux oesophagitis. Gut 1991;32: 1275–1279.

  5. 5.

    , , , et al. The impact of nocturnal symptoms associated with gastroesophageal reflux disease on health-related quality of life. Arch Intern Med 2001;161: 45–52.

  6. 6.

    , , , et al. Nighttime heartburn is an under-appreciated clinical problem that impacts sleep and daytime function: The results of a Gallup survey conducted on behalf of the American Gastroenterological Association. Am J Gastroenterol 2003;98: 1487–1493.

  7. 7.

    , , , et al. The burden of illness of gastro-oesophageal reflux disease: Impact on work productivity. Aliment Pharmacol Ther 2003;17: 1309–1317.

  8. 8.

    , , , et al. Health-related quality-of-life and quality-days incrementally gained in symptomatic nonerosive GERD patients treated with lansoprazole or ranitidine. Dig Dis Sci 2001;46: 2416–2423.

  9. 9.

    , , , et al. Health-related quality of life outcomes of omeprazole versus ranitidine in poorly responsive symptomatic gastroesophageal reflux disease. Dig Dis 1998;16: 284–291.

  10. 10.

    , , , et al. The Pittsburgh Sleep Quality Index: A new instrument for psychiatric practice and research. Psychiatry Res 1989;28: 193–213.

  11. 11.

    , , . The validity and reproducibility of a work productivity and activity impairment instrument. Pharmacoeconomics 1993;4: 353–365.

  12. 12.

    US Department of Labor, Bureau of Labor Statistics. News release: Employer costs for employee compensation—December 2003. US Dept of Labor, Bureau of Labor Statistics: Washington, DC, 2004. USDL:04–288.

  13. 13.

    , , . Lansoprazole and esomeprazole in symptomatic GERD. A double-blind, randomised, multicentre trial in 3000 patients confirms comparable symptom relief. Clin Drug Invest 2003;23: 69–84.

  14. 14.

    , , , et al. Esomeprazole: A review of its use in the management of acid-related disorders in the US. Drugs 2002;62: 1091–1118.

  15. 15.

    , . Sleep-related gastro-oesophageal reflux: Provocation with a late evening meal and treated with acid suppression. Aliment Pharmacol Ther 1998;12: 1033–1038.

  16. 16.

    , , , et al. Quality of life in relation to symptoms in patients with gastro-oesophageal reflux disease—An analysis based on the ProGERD initiative. Aliment Pharmacol Ther 2003;18: 767–776.

  17. 17.

    , . Evolution of insomnia: Current status and future direction. Sleep Med 2004;5(Suppl 1):S23–S30.

  18. 18.

    , , , et al. Validity of a work productivity and activity impairment questionnaire for patients with symptoms of gastroesophageal reflux disease (WPAI-GERD)—Results from a cross-sectional study. Value Health 2002;5: 106–113.

Download references

Acknowledgements

This study was supported by AstraZeneca LP, Wilmington, Delaware.

We gratefully acknowledge Assunta Cuccia for trial management; Kathleen Spreen for her contribution to the study concept and design; Cheryl B. Marple for her assistance with the use of the assessment instruments; John Monyak and Charles Ling for statistical support; and Donna Curtis, Peter Todd, and Mary Wiggin for editorial assistance (funded by AstraZeneca LP). We also thank the other study team members, the staff of ICON Clinical Research and Quintiles Central Laboratory, the study site staff, all the patients who participated in the study, and the following primary investigators: J.D. Angeloni, Bala Cynwyd, PA; M.S. Avila, Hialeah, FL; F. Avni, Lake Worth, FL; J. Beckwith, Fort Worth, TX; W. Berry, Longmont, CO; M. Bowles, Wichita, KS; S. Brady, Naples, FL; R. Broker, Simpsonville, SC; P. Chen, Corpus Christi, TX; D.C. Chua, Oakbrook Terrace, IL; F. Cortese, Butte, MT; L.I. Cowan, Thornville, OH; A. Dahdul, Springfield, MA; S. Desautels, Salt Lake City, UT; J. Doyle, Lexington, KY; S. Duckor, Orange, CA; F. Eder, Endwell, NY; A. Elashker, Kingston, NY; S.K. Elliott, Evansville, IN; J. Fidelholtz, Cincinnati, OH; V. Fishbein, Hillsborough, NJ; C.L. Fisher, Newport News, VA; G.M. Flippo, Birmingham, AL; S. Gaddam, Garden Grove, CA; E. Gallup, Overland Park, KS; W.P. Gilbert, Johnson City, TN; H. Giller, Clive, IA; G.R. Gonzales, West Valley City, UT; R. Gupta, Florala, AL; C. Hall, Jackson, MS; T.M. Howard, Huntsville, AL; J. Hurtado, Tucson, AZ; W. Ignatowicz, Hillsboro, NJ; M. Jacobs, Las Vegas, NV; J.V. Jones, Jr., Ruston, LA; A.J. Kivitz, Duncansville, PA; V. Kolli, El Paso, TX; R. Krause, Chattanooga, TN; F.T. Kucer, Sellersville, PA; M. Kurtz, Oceanside, CA; T. Littlejohn, III, Winston-Salem, NC; J. Lowe, Ogden, UT; G.M. Mula, Covington, LA; R. Murphy, North Little Rock, AR; D. Pambianco, Charlottesville, VA; N. Patel, Kettering, OH; D.M. Paulson, Richmond, VA; K.J. Pierce, Northville, MI; J.E. Poulos, Fayetteville, NC; S. Prohaska, Kansas City, MO; M. Raikhel, Torrance, CA; C. Randall, San Antonio, TX; D. Riff, Anaheim, CA; M.A. Ringold, Christiansburg, VA; C. Rohr, Saginaw, MI; G. Rosman, Egg Harbor Township, NJ; S. Roth, Phoenix, AZ; L. Schmidt, Tucson, AZ; H. Schwartz, Miami, FL; L. Serbousek, Oklahoma City, OK; U. Shah, Hollywood, MD; G. Silver, Clearwater, FL; J. Stoker, Flint, MI; C. Strout, Mt. Pleasant, SC; G. Szenkiel, Perth Amboy, NJ; R. Tamayo, Altamonte Springs, FL; A.S. Thannoun, Amarillo, TX; J. Van Valkenburg, Medford, OR; J.L. Wang, Jefferson City, MO; S.J. Wegley, Seattle, WA; B.D. Winston, Houston, TX; A.H. Wong, Boca Raton, FL.

Author information

Affiliations

  1. Eastern VA School of Medicine, Norfolk, Virginia

    • David A Johnson
  2. Lynn Health Science Institute, Oklahoma University Health Sciences Center, Oklahoma City, Oklahoma

    • William C Orr
  3. AstraZeneca LP, Wilmington, Delaware

    • Joseph A Crawley
    • , Barry Traxler
    • , Joseph McCullough
    •  & Kurt A Brown
  4. Henry Ford Hospital, Detroit, Michigan

    • Thomas Roth

Authors

  1. Search for David A Johnson in:

  2. Search for William C Orr in:

  3. Search for Joseph A Crawley in:

  4. Search for Barry Traxler in:

  5. Search for Joseph McCullough in:

  6. Search for Kurt A Brown in:

  7. Search for Thomas Roth in:

Corresponding author

Correspondence to David A Johnson.

About this article

Publication history

Received

Accepted

Published

DOI

https://doi.org/10.1111/j.1572-0241.2005.00285.x